A study led by Andrew Osterland, PharmD, and colleagues from Ontada examined the use of first-line nivolumab plus ipilimumab (1L NIVO+IPI) in patients with metastatic renal cell carcinoma (mRCC) within the U.S. Oncology Network. By analyzing electronic medical records of 187 patients treated between 2018 and 2022, the researchers compared real-world outcomes to those from the CheckMate 214 clinical trial, which underpinned the approval of this combination therapy. The findings, published in JCO Clinical Cancer Informatics, highlight the treatment’s performance in routine clinical practice.
Why Was This Study Conducted?
Randomized controlled trials (RCTs) like CheckMate 214 are the benchmark for assessing treatment efficacy, but their strict eligibility criteria often exclude patients seen in everyday practice. This study aimed to bridge that gap by gathering real-world evidence from community oncology settings, offering insights into how NIVO+IPI performs in a broader, less controlled patient population.
How Did Real-World Patients Differ from CheckMate 214 Participants?
The real-world cohort presented more challenging cases compared to the CheckMate 214 trial:
- Performance Status: 24.5% of real-world patients had an ECOG performance status of 2 or higher, whereas the trial included none (0%).
- Risk Level: 39.6% were classified as poor risk by the International Metastatic RCC Database Consortium, compared to 21.4% in the trial.
- Brain Metastases: 6.4% had brain metastases, a group entirely excluded from CheckMate 214.
These differences reflect a sicker, more diverse patient group in the real-world setting, with a median age of 63 and 34% categorized as poor-risk.
How Did Outcomes Compare to CheckMate 214?
Despite the tougher patient profile, real-world outcomes aligned closely with trial results:
- Progression-Free Survival (PFS): The median PFS was 11.1 months, comparable to 12.4 months in CheckMate 214.
- Response Rates: 43.3% of patients responded to treatment, nearly identical to the trial’s 42.4%. Note that real-world responses were physician-documented and may not strictly follow the RECIST criteria used in the trial.
- Overall Survival (OS): The median OS was 38.4 months, slightly below the trial’s 47.7 months. This difference may stem from a shorter follow-up period (22.4 months vs. 99.1 months in CheckMate 214).
These findings suggest that NIVO+IPI maintains its effectiveness outside the controlled trial environment.
How Did Treatment-Related Adverse Events (TRAEs) Compare?
Adverse event reporting differed significantly:
- Incidence: Only 48% of real-world patients had documented TRAEs, all within 6 months of starting treatment, compared to 94% in CheckMate 214. This lower rate likely reflects less rigorous documentation in routine practice versus the trial’s systematic monitoring.
- Consistency: The types of TRAEs observed in the real-world study mirrored those in CheckMate 214, indicating similar safety profiles despite the reporting gap.
These variations highlight the challenges of comparing real-world and trial data, where documentation practices can influence results.
What Are the Clinical Implications?
The study confirms that NIVO+IPI remains effective in real-world community oncology settings, even among patients with more severe disease than those in CheckMate 214. With most patients followed for at least 18 months, the findings enhance our understanding of the treatment’s long-term benefits outside RCTs. This supports its broader application in routine care, providing reassurance to clinicians treating diverse mRCC patients.
In essence, this real-world analysis validates the clinical trial outcomes, demonstrating that NIVO+IPI is a robust first-line option for mRCC in everyday practice.
